&nbsp;

Drugs Used:

letrozole,

ribociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ANASRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

anastrozole

Exceptional Access Program

Drugs Used:

anastrozole,

ribociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

EXEMRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

exemestane

Exceptional Access Program

Drugs Used:

exemestane,

ribociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ANASPALB

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

anastrozole

Exceptional Access Program

palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria

Drugs Used:

anastrozole,

palbociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

EXEMPALB

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

exemestane

Exceptional Access Program

Drugs Used:

exemestane,

palbociclib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

APAL

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria

Exceptional Access Program

apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria

Drugs Used:

apalutamide

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

BRIG

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria

Drugs Used:

brigatinib

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

VENE+RITU

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

BORTDEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Selinexor and Dexamethasone for Previously Treated Multiple Myeloma

ODB - General Benefit

dexamethasone

Exceptional Access Program

selinexor - In combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

FLVSRIBO

Cancer Type:

Breast

Intent: Palliative

Funding:

Exceptional Access Program

ODB - General Benefit

fulvestrant

Drugs Used:

ribociclib ,

fulvestrant

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ABEMLETR

Cancer Type:

Breast

Intent: Adjuvant, Palliative

Funding:

Exceptional Access Program

abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria

ODB - General Benefit

letrozole

Drugs Used:

abemaciclib,

letrozole